Assessment of DealThe deal looks good, adding 500 pharmacies, $16M in revenue and $600K in EBITDA. There will be some synergies across the other businesses and customer/product diversification improves nicely. It represents about 1/3rd of the current expected 2021 revenue. It looks good and the market agrees today.
So said 5iResearch last week. GLTA